Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN A versus PFIZERPEN G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN A versus PFIZERPEN G.
PFIZERPEN-A vs PFIZERPEN G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition.
1-2 million units intramuscularly or intravenously every 4 hours; or continuous intravenous infusion of 20-30 million units per day.
2-4 million units (1.2-2.4 g) IV every 4-6 hours; maximum 24 million units per day.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease (ESRD). In neonates, half-life ranges 2-4 hours.
Terminal elimination half-life is 30-60 minutes in patients with normal renal function; prolonged to 2-10 hours in renal impairment (CrCl <10 mL/min).
Primarily renal (60-70% unchanged via glomerular filtration and tubular secretion); hepatic metabolism minor (<10%); biliary/fecal elimination <10%.
Primarily renal excretion via glomerular filtration and tubular secretion; 60-90% of dose excreted unchanged in urine within 6 hours. Biliary excretion accounts for less than 10%.
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)